X连锁低磷血症不仅是骨骼疾病,也是一种慢性炎症状态
本研究为前瞻性多中心横断面研究,检测28例X连锁低磷血症(XLH)患者(17例儿童,其中6例接受标准治疗、11例接受burosumab治疗)及19例对照者外周血单核细胞中8种炎症标志物的转录表达,并体外评估维生素D对破骨细胞形成的影响。结果显示XLH患者多数炎症标志物表达显著升高,破骨细胞形成显著受损,burosumab亚组与标准治疗亚组间无差异。作者首次描述XLH存在独特炎症特征,并推测炎症可能参与其骨骼外并发症。
要点
- XLH患者外周血单核细胞中多数炎症标志物表达较健康对照显著升高。
- XLH患者破骨细胞形成显著受损,成熟破骨细胞炎症标志物水平较高。
- burosumab亚组与标准治疗亚组间炎症标志物表达无差异。
核心结论
- 作者首次描述XLH患者存在独特的炎症特征,并推测炎症可能在XLH的骨骼外并发症中起关键作用。
研究设计与样本
- 前瞻性、多中心、横断面研究,纳入28例XLH患者(17例儿童,其中6例接受标准治疗、11例接受burosumab治疗)和19例健康对照。
- 采用实时定量聚合酶链反应检测外周血单核细胞中8种炎症标志物(Il6、Il8、Il1β、CXCL1、CCL2、CXCR3、Il1R、Il6R)的转录表达。
- 体外评估天然/活性维生素D对XLH患者外周血单核细胞来源破骨细胞形成的影响。
主要发现
- 与对照组相比,XLH患者外周血单核细胞中多数炎症标志物的表达显著增加。
- burosumab亚组与标准治疗亚组之间未观察到差异。
- XLH患者破骨细胞形成显著受损。
- XLH成熟破骨细胞炎症标志物水平较高,但burosumab亚组来源的细胞中较低(与标准治疗亚组相反)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: X-linked hypophosphatemia (XLH) is a rare genetic disease caused by a primary excess of fibroblast growth factor 23 (FGF23). FGF23 has been associated with inflammation and impaired osteoclastogenesis, but these pathways have not been investigated in XLH. OBJECTIVE: This work aimed to evaluate whether XLH patients display peculiar inflammatory profile and increased osteoclastic activity. METHODS: We performed a prospective, multicenter, cross-sectional study analyzing transcript expression of 8 inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R) by real-time quantitative polymerase chain reaction on peripheral blood mononuclear cells (PBMCs) purified from total blood samples extracted from patients and healthy control individuals. The effect of native/active vitamin D on osteoclast formation was also assessed in vitro from XLH patients' PBMCs. RESULTS: In total, 28 XLH patients (17 children, among them 6 undergoing standard of care [SOC] and 11 burosumab therapy) and 19 controls were enrolled. Expression of most inflammatory markers was significantly increased in PBMCs from XLH patients compared to controls. No differences were observed between the burosumab and SOC subgroups. Osteoclast formation was significantly impaired in XLH patients. XLH mature osteoclasts displayed higher levels of inflammatory markers, being however lower in cells derived from the burosumab subgroup (as opposed to SOC). CONCLUSION: We describe for the first time a peculiar inflammatory profile in XLH. Since XLH patients have a propensity to develop arterial hypertension, obesity, and enthesopathies, and because inflammation can worsen these clinical outcomes, we hypothesize that inflammation may play a critical role in these extraskeletal complications of XLH.
引用
- Méaux MN, Alioli C, Linglart A, et al. X-Linked Hypophosphatemia, Not Only a Skeletal Disease But Also a Chronic Inflammatory State. J Clin Endocrinol Metab. 2022. PMID: 36112422. doi:10.1210/clinem/dgac543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。